|
|
|
|
| LEADER |
03603nam a2200301 u 4500 |
| 001 |
EB002002387 |
| 003 |
EBX01000000000000001165288 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a Evidence summaries: new medicines - integrated process statement
|h Elektronische Ressource
|c National Institute for Health and Care Excellence
|
| 260 |
|
|
|a London
|b National Institute for Health and Care Excellence (NICE)
|c 2013, 7 May 2013
|
| 300 |
|
|
|a 1 PDF file (20 pages)
|
| 653 |
|
|
|a United Kingdom
|
| 653 |
|
|
|a Drug Evaluation / standards
|
| 653 |
|
|
|a Evidence-Based Medicine
|
| 653 |
|
|
|a Drug Approval
|
| 710 |
2 |
|
|a National Institute for Health and Care Excellence (Great Britain)
|
| 740 |
0 |
2 |
|a Evidence summaries: process guide
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Process and methods
|
| 500 |
|
|
|a "This is not the current process. From February 2017, evidence summaries were developed using the evidence summaries: process guide"--Page 4
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK425825
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a This integrated process statement has been produced to explain how 'Evidence summaries: new medicines' (ESNMs) are developed. It provides an overview of the key process principles and describes all stages of the development of ESNMs. These procedures are designed to ensure that a robust, quality-assured, commentary is developed for the NHS in an open, transparent and timely way, with appropriate input from key groups. The NICE Medicines and Prescribing Centre provides advice and support for delivering safety, efficiency and effectiveness in the use of medicines. The Medicines and Prescribing Centre is responsible for developing ESNMs. ESNMs provide a summary of the published evidence for selected new medicines that are considered to be of significance to the NHS. This includes new indications for existing medicines and new formulations of existing medicines. The strengths and weaknesses of the relevant evidence are critically reviewed within each ESNM.
|
| 520 |
|
|
|a Importantly, an ESNM does not constitute formal NICE guidance and this is clearly stated on each publication. The context of the rest of the evidence informing the management of the licensed indication(s) or anticipated licensed indication(s) for the new medicine is also summarised to assist local decision making. The NHS Constitution gives patients the right to expect that decisions about the funding of medicines and treatments will be made rationally, following proper consideration of the evidence. ESNMs help provide consistent access to the best available information on a medicine to guide local decision-making, for example within a Clinical Commissioning Group (CCG), an NHS Trust, or across a local health economy. This information from NICE will help to avoid potential duplication of effort when different organisations are producing their own evidence summaries. The topics for ESNMs are selected in collaboration with the existing NICE topic selection programme.
|
| 520 |
|
|
|a Two types of topics are considered: 1. A medicine recently marketed in the UK.2. A medicine that may be marketed in the UK within the next 6-12 months. In both cases, topics are considered for an ESNM only if a NICE technology appraisal (TA) is not planned or in progress, unless the technology appraisal programme will not publish an appraisal consultation document (ACD) within 6 months of the medicine's launch
|